SSA
TCON

Schonfeld Strategic Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,100
Closed -$492K – 2194
2020
Q4 		$492K Buy
+2,100
New +$292K 0.01% 1043

Other funds holding TCON

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Schonfeld Strategic Advisors's TCON Position: Q1 2021 in Review

Schonfeld Strategic Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2021, closing a stake of 2,100 shares — an estimated $492K sold.

Schonfeld Strategic Advisors first reported a position in TCON in Q4 2020 and held it in 1 quarter. The position peaked at $492K in Q4 2020. 42 funds tracked by Wall St. Rank hold TCON as of Q1 2021.

  • Schonfeld Strategic Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 2,100 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $492K.
  • Schonfeld Strategic Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $492K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.